Biogen BIIB and Apellis Pharmaceuticals APLS announced a definitive agreement under which Biogen will acquire all outstanding ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Biogen Inc. (BIIB), which belongs to the Zacks ...

Biogen (BIIB) partners with Alloy Therapeutics for antisense oligonucleotide platform access. RBC cuts price target to $213 while maintaining Outperform.

Its first-quarter expenses will be notably higher than anticipated.

Leqembi efficacy doubts in APOE4 subgroups raise regulatory and commercial risks for Eisai and Biogen; see real-world data ...

Market positioning reflects broader sentiment shifts aligned with nasdaq composite movements.

Biogen (BIIB) just cleared two important milestones, with FDA approval of a new High Dose Regimen for SPINRAZA in spinal muscular atrophy and positive Phase 2 data for litifilimab in cutaneous lupus ...

The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus ...

Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...